Stockscreener 앱 받기
8.38
10.55%
0.80
시간 외 거래:
8.34
-0.04
-0.48%
전일 마감가:
$7.58
열려 있는:
$7.7
하루 거래량:
19.55M
Relative Volume:
0.77
시가총액:
$8.78B
수익:
$113.29M
순이익/손실:
$-351.47M
주가수익비율:
-21.50
EPS:
-0.3898
순현금흐름:
$-309.19M
1주 성능:
+20.40%
1개월 성능:
+18.36%
6개월 성능:
+295.28%
1년 성능:
+316.92%
1일 변동 폭
$7.665
$8.39
1주일 범위
$6.94
$8.39
52주 변동 폭
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
명칭
Immunitybio Inc
전화
(844) 696-5235
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.38 | 7.94B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2025-05-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 개시 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | BTIG Research | Buy |
| 2023-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 개시 | Jefferies | Buy |
모두보기
Immunitybio Inc 주식(IBRX)의 최신 뉴스
Immunitybio earnings loom amid Anktiva growth, FDA scrutiny By Investing.com - Investing.com Canada
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) on May 26, 2026 - The Globe and Mail
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
IBRX Stock Climbs As ANKTIVA Growth And Global Rollout Accelerate - StocksToTrade
Why ImmunityBio Stock Is Surging On Wednesday? - Benzinga
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX stock climbs: Founder says AI robot built to mass-produce cancer-killing immune cells ships this month - MSN
IBRX Stock Climbs: Founder Says AI Robot Built To Mass-Produce Cancer-Killing Immune Cells Ships This Month - Stocktwits
IBRX Stock Jumps After-Hours: Bulls Cheer ‘Unstoppable’ Global Expansion Amid US Regulatory Heat For Anktiva - Stocktwits
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
IBRX Lead Plaintiff Deadline is May 26, 2026Injured Stockholde - The National Law Review
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
INVESTOR DEADLINE ALERT: ImmunityBio, Inc. (IBRX) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Globe and Mail
2026-05-05 | IBRX Lead Plaintiff Deadline is May 26, 2026Injured Stockholders Should Contact Robbins LLP for Information About Their Rights Against ImmunityBio, Inc | NDAQ:IBRX | Press Release - Stockhouse
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting - BioSpace
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
IBRX Deadline Alert: The Gross Law Firm Reminds ImmunityBio, Inc. (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - GlobeNewswire
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Morningstar
ImmunityBio to Report Q1 Earnings: What's in the Cards? - Yahoo Finance
IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - marketscreener.com
IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is ImmunityBio, Inc. (IBRX) A Good Stock To Buy Now? - Insider Monkey
IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm - PR Newswire
D. Boral Capital Maintains ImmunityBio (IBRX) Buy Recommendation - MSN
symbol__ Stock Quote Price and Forecast - CNN
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue Growth - Insider Monkey
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - Morningstar
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - TMX Newsfile
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Forecast, Price Target & Analyst Ratings | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug CapabilitiesImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt - PR Newswire
Bladder Cancer Vaccines Market to Reach USD 1,365.83 Million - openPR.com
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Immunitybio Inc (IBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):